Opus Genetics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Foundation Fighting Blindness RD Fund and Foundation Fighting Blindness, Inc. have reduced their stake in Opus Genetics, Inc. below the 5% reporting threshold.
NASDAQ
Foundation Fighting Blindness entities have reduced their beneficial ownership in Opus Genetics, Inc. to 8.0% following a share sale on December 9, 2025.
NASDAQ
SCHEDULE 13D/A: Foundation Fighting Blindness Entities Increase Stake in Opus Genetics to 15.9% Following Preferred Stock Conversion
Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fight Blindness, Inc. have increased their beneficial ownership in Opus Genetics, Inc. to 15.9% of common stock following the automatic conversion of preferred shares.